edoxaban

Chemical data

Formula

C24H30ClN7O4S

Molecular weight

548.1 g/mol

IUPAC name

N'-(5-chloro-2-pyridinyl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide

SMILES

CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C

InChIKey

HGVDHZBSSITLCT-JLJPHGGASA-N

XLogP

1.4

Polar surface area

165 Ų

H-bond donors

3

H-bond acceptors

8

Formal charge

0

via PubChem

• Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.The New England journal of medicine · 2018
• Edoxaban in cardiovascular disease management: Review.British journal of clinical pharmacology · 2022
• Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.European heart journal · 2019
• Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.Circulation · 2023
• Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.Lancet (London, England) · 2019

via PubMed